Calreticulin arms NK cells against leukemia

Calreticulin (CALR) exposed on the surface of cancer cells succumbing to therapy delivers robust phagocytic signals that support the activation of adaptive anticancer immune responses. Recent data from our group demonstrate that spontaneous CARL exposure on leukemic blasts also supports innate antic...

Descripción completa

Detalles Bibliográficos
Autores principales: Fucikova, Jitka, Kline, Justin P., Galluzzi, Lorenzo, Spisek, Radek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959451/
https://www.ncbi.nlm.nih.gov/pubmed/32002282
http://dx.doi.org/10.1080/2162402X.2019.1671763
_version_ 1783487600901750784
author Fucikova, Jitka
Kline, Justin P.
Galluzzi, Lorenzo
Spisek, Radek
author_facet Fucikova, Jitka
Kline, Justin P.
Galluzzi, Lorenzo
Spisek, Radek
author_sort Fucikova, Jitka
collection PubMed
description Calreticulin (CALR) exposed on the surface of cancer cells succumbing to therapy delivers robust phagocytic signals that support the activation of adaptive anticancer immune responses. Recent data from our group demonstrate that spontaneous CARL exposure on leukemic blasts also supports innate anticancer immunity by natural killer (NK) cells via an indirect mechanism relying on myeloid CD11c(+)CD14(+) cells.
format Online
Article
Text
id pubmed-6959451
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-69594512020-01-30 Calreticulin arms NK cells against leukemia Fucikova, Jitka Kline, Justin P. Galluzzi, Lorenzo Spisek, Radek Oncoimmunology Commentary Calreticulin (CALR) exposed on the surface of cancer cells succumbing to therapy delivers robust phagocytic signals that support the activation of adaptive anticancer immune responses. Recent data from our group demonstrate that spontaneous CARL exposure on leukemic blasts also supports innate anticancer immunity by natural killer (NK) cells via an indirect mechanism relying on myeloid CD11c(+)CD14(+) cells. Taylor & Francis 2019-10-09 /pmc/articles/PMC6959451/ /pubmed/32002282 http://dx.doi.org/10.1080/2162402X.2019.1671763 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Commentary
Fucikova, Jitka
Kline, Justin P.
Galluzzi, Lorenzo
Spisek, Radek
Calreticulin arms NK cells against leukemia
title Calreticulin arms NK cells against leukemia
title_full Calreticulin arms NK cells against leukemia
title_fullStr Calreticulin arms NK cells against leukemia
title_full_unstemmed Calreticulin arms NK cells against leukemia
title_short Calreticulin arms NK cells against leukemia
title_sort calreticulin arms nk cells against leukemia
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959451/
https://www.ncbi.nlm.nih.gov/pubmed/32002282
http://dx.doi.org/10.1080/2162402X.2019.1671763
work_keys_str_mv AT fucikovajitka calreticulinarmsnkcellsagainstleukemia
AT klinejustinp calreticulinarmsnkcellsagainstleukemia
AT galluzzilorenzo calreticulinarmsnkcellsagainstleukemia
AT spisekradek calreticulinarmsnkcellsagainstleukemia

Ejemplares similares